Acurx Pharmaceuticals Inc., a late-stage biopharmaceutical company specializing in developing a new class of antibiotics, has announced a warrant inducement agreement with a holder of existing warrants. This agreement involves the exercise of warrants to purchase up to 4,445,435 shares of common stock at a reduced exercise price of $0.675 per share, generating gross proceeds of approximately $2.67 million. In exchange for this exercise, the investors received G-1 and G-2 warrants to purchase up to 8,890,870 shares of common stock. The G-1 Warrants are immediately exercisable at an exercise price of $0.425 per share, while the G-2 Warrants will become exercisable upon shareholder approval. The company plans to use the net proceeds for working capital and general corporate purposes. The transaction is expected to close by June 20, 2025, pending customary closing conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.